Moon Rabbit: 2024
Moon Rabbit had a busy 2023, continuing to build, grow, reinforce its roster of clients, and continue to build a team of talented people looking to do exceptional work.
If you are not happy with the results below please do another search
Moon Rabbit had a busy 2023, continuing to build, grow, reinforce its roster of clients, and continue to build a team of talented people looking to do exceptional work.
Last year Mosaic Group re-imagined the entirety of the patient access journey to help more people live healthier, fulfilling lives. As part of the global IPG Health network, we are dedicated to helping our clients break down the walls of access so they can build a more connected and seamless access experience for the patients they serve and their brands.
NaviSync stayed true to its ongoing mission of pursuing steady, sustainable growth and continued its decade-long commitment to market access.
Neon exceeded all expectations this past year with 10 new, significant client engagements and double-digit revenue growth on an already lofty base.
“Transformative Impact. It’s what we do, it’s in our DNA. It’s how at Ogilvy Health – we create, strategize, experience, and ultimately, how we influence.”
Coming off another year of double-digit growth, CEO Deb Deaver credits the agency’s ability to not only come up with the big consumer idea but also build a patient-centric experience around it.
Peregrine Market Access had an influx of new business in 2023 as pharmaceutical and biotechnology manufacturers looked for expertise and a trusted partner to help them navigate the complexities of the healthcare marketplace.
This was the year the vision came into high definition,” says Doug Fulling, president of Precision Value & Health. “The foundational teams – patient, payer, provider – have developed a unified offering of unprecedented depth, matching our clients in a united pursuit to ensure all patients have access to life-changing therapies.”
ProHealth expanded relationships with existing clients by adding 10 new brands to its portfolios, which helped lead to an “incredible” 40 percent revenue growth from the previous year.
The agency continued its trajectory from consumer health care into biopharma, with 74 percent of revenues coming from health care, and Rx products representing its largest sector.